glp-1 agonist fda approval Novo Nordisk's Wegovy® pill (oral semaglutide 25 mg, once daily) has just been approved by the US as the first oral GLP‑1 receptor for long‑term weight management and CV risk The first ever FDA-approved GLP-1
Description
Murakami, R
Novo Nordisk) oral tablets are now available in sufficient quantities to support initiation of GLP-1 RA treatment in type 2 diabetes mellitus (T2DM) and can be prescribed in line with National Institute for Health and Care Excellence (NICE) guidance
Hupe-Sodmann, K

If confirmed, these drugs could offer a novel pharmacological approach to addressing both metabolic and behavioral disorders, bridging the gap between metabolic health and neuropsychiatric conditions

Sixth, we were unable to evaluate changes in insulin resistance following the use of GLP-1 RAs due to the limited availability of data on insulin resistance indices in the TriNetX database